- Home
- OVID vs MIST Comparison
OVID vs MIST Comparison
Compare OVID & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- MIST
- Stock Information
- Founded
- OVID 2014
- MIST 2003
- Country
- OVID United States
- MIST Canada
- Employees
- OVID N/A
- MIST N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- MIST Health Care
- Exchange
- OVID Nasdaq
- MIST Nasdaq
- Market Cap
- OVID 85.2M
- MIST 81.5M
- IPO Year
- OVID 2017
- MIST N/A
- Fundamental
- Price
- OVID $1.06
- MIST $1.70
- Analyst Decision
- OVID Strong Buy
- MIST Strong Buy
- Analyst Count
- OVID 5
- MIST 3
- Target Price
- OVID $4.04
- MIST $13.00
- AVG Volume (30 Days)
- OVID 216.9K
- MIST 524.5K
- Earning Date
- OVID 11-12-2024
- MIST 11-12-2024
- Dividend Yield
- OVID N/A
- MIST N/A
- EPS Growth
- OVID N/A
- MIST N/A
- EPS
- OVID N/A
- MIST N/A
- Revenue
- OVID $631,695.00
- MIST N/A
- Revenue This Year
- OVID $21.51
- MIST N/A
- Revenue Next Year
- OVID $7,300.79
- MIST N/A
- P/E Ratio
- OVID N/A
- MIST N/A
- Revenue Growth
- OVID 113.21
- MIST N/A
- 52 Week Low
- OVID $0.68
- MIST $1.12
- 52 Week High
- OVID $4.10
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- OVID 37.15
- MIST 54.46
- Support Level
- OVID $1.11
- MIST $1.66
- Resistance Level
- OVID $1.47
- MIST $1.88
- Average True Range (ATR)
- OVID 0.11
- MIST 0.16
- MACD
- OVID -0.02
- MIST 0.02
- Stochastic Oscillator
- OVID 6.82
- MIST 42.86
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).